Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Ningning Zhang(Tianjin Medical University Cancer Institute and Hospital), Xiaolu Tao(Shanghai Harbour Engineering Design & Research Institute), Ming Luo(Tianjin Medical University Cancer Institute and Hospital), Jie Shen(Nanjing Drum Tower Hospital), Shukui Qin(Sichuan University), Di Yang(Shanghai Harbour Engineering Design & Research Institute), Yanqiao Zhang(Harbin Medical University), Ruixuan Luo(Shanghai Harbour Engineering Design & Research Institute), Chongyuan Xu(Nanfang Hospital), Jihui Hao(Tianjin Medical University Cancer Institute and Hospital), Guijie Xin(First Bethune Hospital of Jilin University), Jingdong Zhang(Wenzhou Medical University), Shuwen Zhang(Tianjin Medical University Cancer Institute and Hospital), Aibing Xu(Nantong Tumor Hospital), Yajin Chen(Sun Yat-sen University), Ge Yu(First Bethune Hospital of Jilin University), Yanxia He(Shanghai Harbour Engineering Design & Research Institute), Jun Yao(First Affiliated Hospital of Henan University of Science and Technology), Fei Zheng(Beijing Friendship Hospital), Gang Wang(Baoji City Central Hospital), Meijuan Gao(Shanghai Harbour Engineering Design & Research Institute), Shanzhi Gu(Hunan Cancer Hospital), Yabing Guo(Nanfang Hospital), Junqi Niu(First Hospital of Jilin University), Tian Liu(Tianjin Medical University Cancer Institute and Hospital), Nan Cao(Shanghai Harbour Engineering Design & Research Institute)
Cited by 4
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
|Liver International|2019|591